A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Yibo Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, DNA Damage, Apoptosis, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
DNA damage-based drugs are widely used in cancer therapy, yet resistance remains a major challenge. In this study, we uncovered a non-DNA repair mechanism contributing to resistance in pancreatic ductal adenocarcinoma (PDAC). We show that in gemcitabine-resistant PDAC cells, CIP2A undergoes ubiquitin-mediated degradation, resulting in enhanced PP2A phosphatase activity. This leads to the dephosphorylation of ATR at Ser428 in the cytoplasm, promoting the formation of the prolyl cis-isomeric form of ATR at its Ser428-Pro429 motif. The resulting cis-ATR functions as a mitochondria-targeted antiapoptotic protein (mtATR). Surprisingly, resistant PDAC cells paradoxically accumulated both mtATR and proapoptotic tBid at the mitochondria, forming a stable mtATR-tBid complex that induces a state of apoptotic dormancy. Disrupting this complex, either with the PP2A inhibitor LB-100 or a cytoplasmic ATR-specific antibody, reactivates the pre-accumulated tBid and restores apoptosis in resistant PDAC cells. In an orthotopic PDAC mouse model, LB-100 alone significantly inhibit gemcitabine-resistant tumor growth by disrupting the mtATR-tBid complex. These findings reveal a previously unrecognized mechanism of resistance to DNA damage-based therapies and identify a novel action mechanism of LB-100, characterized by the CIP2A degradation-mediated PP2A-mtATR-tBid axis. By targeting mtATR-tBid-mediated apoptotic dormancy, this strategy offers a promising approach to restore apoptotic sensitivity in drug-resistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA.
- Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA. Electronic address: yue.zou@utoledo.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Luo, Y., Biswas, H., Makinwa, Y., Liu, S. H., Dong, Z., Liu, J. Y., Zhang, J. T., & Zou, Y. (2025). A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217790
Vancouver
Luo Y, Biswas H, Makinwa Y, Liu SH, Dong Z, Liu JY, et al. A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217790
BibTeX
@article{Luo2025,
author = {Luo, Yibo and Biswas, Himadri and Makinwa, Yetunde and Liu, Shi-He and Dong, Zizheng and Liu, Jing-Yuan and Zhang, Jian-Ting and Zou, Yue},
title = {A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217790}
}
EUVIMED